Abstract
Corticobasal syndrome (CBS) is the classic clinical presentation associated with corticobasal degeneration (CBD) pathology. Approximately half of all CBS cases, however, are caused by other neurodegenerative pathologies. CBS should be suspected when atypical parkinsonism presents with perceptual or motor dysfunction suggestive of perirolandic involvement often accompanied by focal cognitive impairment. Although there are no disease-modifying treatments for CBS, a number of pharmacological, physical, and behavioral interventions focusing on motor, sensory, functional, and cognitive/behavioral deficits can be implemented for symptomatic relief and quality-of-life improvement. Research participation should be encouraged when available. Limited numbers of clinical trials have been pursued in CBS, but it is likely more will be available in the coming years as biomarkers are enabling antemortem prediction of underlying disease pathology, allowing for targeted interventions focused on specific proteinopathies, in particular tauopathies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Suggested Reading
Burrell JR, Hodges JR, Rowe JB. Cognition in corticobasal syndrome and progressive supranuclear palsy: a review. Mov Disord. 2014;29(5):684–93.
Cotter C, Armytage T, Crimmins D. The use of zolpidem in the treatment of progressive supranuclear palsy. J Clin Neurosci. 2010;17(3):385–6.
Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. N Engl J Med. 1999;341(7):543–4.
Dutt S, Binney RJ, Heuer HW, Luong P, Attygalle S, Bhatt P, et al. Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology. 2016;87(19):2016–25.
Josephs KA, Whitwell JL, Tacik P, Duffy JR, Senjem ML, Tosakulwong N, et al. [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol. 2016;132(6):931–3.
Lamb R, Rohrer JD, Lees AJ, Morris HR. Progressive supranuclear palsy and corticobasal degeneration: pathophysiology and treatment options. Curr Treat Options Neurol. 2016;18(9):42.
Lee SE, Rabinovici GD, Mayo MC, Wilson SM, Seeley WW, DeArmond SJ, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011;70(2):327–40.
Marsili L, Suppa A, Berardelli A, Colosimo C. Therapeutic interventions in parkinsonism: corticobasal degeneration. Parkinsonism Relat Disord. 2016;22(Suppl 1):S96–100.
Sha SJ, Ghosh PM, Lee SE, Corbetta-Rastelli C, Jagust WJ, Kornak J, et al. Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. Alzheimers Res Ther. 2015;7(1):8.
Tsai RM, Boxer AL. Therapy and clinical trials in frontotemporal dementia: past, present, and future. J Neurochem. 2016;138(Suppl 1):211–21.
Zhang Y, Walter R, Ng P, Luong PN, Dutt S, Heuer H, et al. Progression of microstructural degeneration in progressive supranuclear palsy and corticobasal syndrome: a longitudinal diffusion tensor imaging study. PLoS One. 2016;11(6):e0157218.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Rojas, J.C., Boxer, A.L. (2019). Treatment of Corticobasal Syndrome. In: Reich, S., Factor, S. (eds) Therapy of Movement Disorders. Current Clinical Neurology. Humana, Cham. https://doi.org/10.1007/978-3-319-97897-0_35
Download citation
DOI: https://doi.org/10.1007/978-3-319-97897-0_35
Published:
Publisher Name: Humana, Cham
Print ISBN: 978-3-319-97896-3
Online ISBN: 978-3-319-97897-0
eBook Packages: MedicineMedicine (R0)